Company

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion
Eli LillyFinanical Reports

Eli Lilly Q3 Revenue Soars 39% to USD 24.4 Billion as Mounjaro Sales Jump 65% and China Revenue Climbs 69%; Full‑Year Guidance Raised to USD 91–92 Billion

Eli Lilly and Company (NYSE: LLY) reported third‑quarter 2026 worldwide revenue of USD 24.4 billion, up 39% year‑on‑year, driven by strong demand for its diabetes and obesity treatments Mounjaro (tirzepatide)…

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

BioMarin Licenses HM15421/GC1134A Subcutaneous Fabry Disease Enzyme Therapy from GC Biopharma and Hanmi in USD 110 Million Deal

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Wanbangde Receives FDA Feedback Endorsing Pivotal Phase III Path for WP205 Mecobalamin Injection in ALS

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Abbisko Therapeutics Completes First Patient Dosing for PRMT5×MTA Inhibitor ABSK131
Abbisko TherapeuticsCancer

Abbisko Therapeutics Completes First Patient Dosing for PRMT5×MTA Inhibitor ABSK131

Novatim and ERIGEN Ink Licensing Pact for Dual-Target CAR-T Therapy KQ-2003
CancerCAR-T

Novatim and ERIGEN Ink Licensing Pact for Dual-Target CAR-T Therapy KQ-2003

AusperBio Gains NMPA Approval for Phase III Trials of AHB-137 in Chronic Hepatitis B
AusperBioClinical trial approval / initiation

AusperBio Gains NMPA Approval for Phase III Trials of AHB-137 in Chronic Hepatitis B

Sanofi to Acquire Vicebio Ltd for Up to USD 1.6 Billion, Advancing Next-Gen Vaccine Development
NASDAQ: SNYSanofi

Sanofi to Acquire Vicebio Ltd for Up to USD 1.6 Billion, Advancing Next-Gen Vaccine Development

Show More